Milestone pharmaceuticals inc. (MIST)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating activities
Net loss for the period

-16,343

-18,289

-12,830

-13,658

-10,452

-9,716

-5,700

-3,588

-4,181

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of property and equipment

24

24

9

2

3

2

3

3

2

Share-based compensation expense (note 4)

981

354

350

276

211

344

85

79

125

Changes in operating assets and liabilities:
Other receivables

1

-229

159

79

-128

257

-55

44

25

Research and development tax credits receivable

106

122

99

93

-26

63

47

-128

-119

Prepaid expenses

-280

-1,672

-1,515

-466

4,100

-71

1,026

-301

644

Operating lease right of use asset, net

-87

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-2,827

-481

2,919

1,653

-571

2,252

1,039

-280

-135

Income taxes payable (receivable)

-

-1

1

-78

22

56

0

-20

16

Net cash used in operating activities

-18,079

-16,603

-8,298

-11,518

-14,733

-7,311

-5,591

-3,421

-4,723

Investing activities
Acquisition of property and equipment

-

-

-

-

-

0

0

0

5

Redemption of short-term investments

-

-

-

-

-

3,014

983

8,034

7,001

Net cash (used in) provided by investing activities

-

-

-

-

-

8,985

-8,017

8,034

6,996

Financing activities
Issuance of common shares on exercise of share options (note 4)

77

19

0

0

25

424

0

7

30

Net cash provided by financing activities

77

21

-731

86,092

25

80,078

0

7

30

Net increase in cash and cash equivalents during the period

-18,002

13,317

-4,323

39,585

-14,708

81,752

-13,608

4,620

2,303